Silence Therapeutics PLC（SLN）股票分析SLNSilence Therapeutics PLC

Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Silence Therapeutics PLC is a good buy right now due to its impressive 5-day price change of +126.61% and a strong RSI of 89.128, indicating strong momentum. The company has also shown significant improvement in its financials, with a gross margin of 97.39% in the latest quarter, which suggests efficient operations. However, the main risk is the ongoing net losses, with a reported net income of -12.27 million USD in Q2 2026, which investors should monitor closely.